Companies › NOBO Medicine
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Poseltinib (NB02) Tyrosine-protein kinase BTK inhibitor | BTK | Phase 2 | Primary CNS Lymphoma (PCNSL); Non Hodgkin Lymphoma (NHL) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07114367 | Poseltinib (NB02) | Phase 1 | Non Hodgkin Lymphoma (NHL) | Oncology | Dec 2026 |
| NCT06737250 | Poseltinib (NB02) | Phase 2 | Primary CNS Lymphoma (PCNSL) | Oncology | Dec 2027 |
TransThera Sciences (Nanjing) Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.